Publications

Overall Survival (Os) in the Imelda Randomized Phase Iii Trial of Maintenance Bevacizumab (Bev) with or Without Capecitabine (Cap) for Her2-Negative Metastatic Breast Cancer (Mbc)

AuthID
P-00G-D2N

Author(s)

Gligorov, J

Bines, J

Alba, E

Mustacchi, G

Cinieri, S

Gupta, V

Pierga, JY

Bozcuk, H

Gaafar, R

Gupta, S

Vivanco, GL

Wang, XJ

Costa, R

Altundag, K

Chmielowska, E

de Ducla, S

Freudensprung, U

Cortes, P

Doval, D

Document Type

Abstract

Year published

2015

Published

in CANCER RESEARCH, ISSN: 0008-5472

Volume: 75, Issue: 9, Pages: P2-17-01-P2-17-01 (2)

Conference

37Th Annual Ctrc-Aacr San Antonio Breast Cancer Symposium, Date: DEC 09-13, 2014, Location: San Antonio, TX, Sponsors: CTRC, AACR

Indexing

Wos^®

Crossref^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1158/1538-7445.sabcs14-p2-17-01

Wos: WOS:000356730201241

Source Identifiers

ISSN: 0008-5472

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

Overall Survival (Os) in the Imelda Randomized Phase Iii Trial of Maintenance Bevacizumab (Bev) with or Without Capecitabine (Cap) for Her2-Negative Metastatic Breast Cancer (Mbc)

Useful Links

Get Help

Federated Authentication (Click on the image)

Overall Survival (Os) in the Imelda Randomized Phase Iii Trial of Maintenance Bevacizumab (Bev) with or Without Capecitabine (Cap) for Her2-Negative Metastatic Breast Cancer (Mbc)

Useful Links

Get Help